On January 15th, 2019, was established in Lisbon the Association Vector B2B – Drug Developing – Association for Research in Biotechnology. Vector B2B resulted from the joint initiative of seven entities, Laboratório Medinfar, SA, BEVAG, Faculty of Medicine, Faculty of Pharmacy and Faculty of Veterinary Medicine of University of Lisbon and University of Coimbra through CNC.IBILI, under the coordination of Technophage, SA.

VectorB2B Collaborative Laboratory has been approved by the Portuguese Foundation for Science and Technology (FCT) Evaluation Committee. This Laboratory will be a one-stop shop for other companies and academic institutions involved in the discovery and development of biological drugs, providing highly qualified bench-to-bedside (B2B) services. VectorB2B aims to bring together: (i) highly qualified human resources in Portugal with knowledge and experience in the discovery and development of biological drugs, (ii) instrumental power in pharmacodynamic and pharmacokinetic analysis and testing, and (iii) cross-cutting services such as systematic reviews, project planning and statistical decision evaluation. It will provide specialized services such as antibody screening, in vitro and in vivo efficacy assays in areas such as ophthalmology, oncology, CNS, etc.; GMP process development and production services.

Collaborative Laboratories are a new R&D institution created in 2017 by FCT that “have as its main objective to create, directly and indirectly, qualified and scientific employment in Portugal through the implementation of research and innovation agendas oriented towards the creation of economic value (…) and address the challenge of the densification of the national territory through growing consolidation of forms of collaboration between science, technology and higher education institutions and the economic and social fabric, namely companies, the health and hospital system, cultural institutions and social organizations. ”